Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIS649 Single Ascending Dose Study in Healthy Subjects
NCT03719443Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Oct 2018
- Primary completion
- Aug 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in IgA nephropathy (IgAN) comparing VIS649 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Oct 2018; status: completed.
02
Drugs
sibeprenlimab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT03719443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03719443.